Effect of Schisandra sphenanthera extract on the concentration of tacrolimus in the blood of liver transplant patients

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 3, 2010, Pages 224-229

  Jiang, W ^a   Wang, X ^a   Xu, X ^a   Kong, L ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Drug interaction; Liver transplantation; Pharmacokinetics; Schisandra sphenanthera extract; Tacrolimus

Indexed keywords

CORTICOSTEROID; DEOXYSCHIZANDRIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; SCHISANDRA SPHENANTHERA EXTRACT; TACROLIMUS; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGITATION; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENTIATION; EVENING DOSAGE; FEMALE; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; SCHISANDRA SPHENANTHERA; SCHISANDRACEAE; SCHOOL CHILD; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77949451360     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48224     Document Type: Article

References (32)

1. Assan R, Fredj G, Larger E, Feutren G, Bismuth H. FK 506/fluconazole interaction enhances FK 506 nephrotoxicity. Diabete Metab. 1994; 20: 49-52.
2. Bhaloo S, Prasad GV. Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: A Case Report. Transplant Proc. 2003; 35: 2449-2451.
3. Canaparo R, Finnström N, Serpe L, Nordmark A, Muntoni E, Eandi M, Rane A, Zara GP. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin Exp Pharmacol Physiol. 2007; 34: 1138-1144.
4. Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. John's wort and implication in drug development.Curr PharmDes. 2008; 14: 1723-1742.
5. Dresser GK, Spence JD, Bailey DG. Pharmaco-kinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000; 38: 41-57.
6. Furlan V, Perello L, Jacquemin E, Debray D, Taburet AM. Interactions between FK 506 and rifamycin or erythromycin in pediatric liver recipients. Transplantation. 1995; 59: 1217-1218.
7. Gödtel-Armbrust U, Metzger A, Kroll U, Kelber O, Wojnowski L. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort. Naunyn Schmiedebergs Arch Pharmacol. 2007; 375: 377-382.
8. Goodwin B, Moore LB, Stoltz CM, McKee DD, Kliewer SA. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol. 2001; 60: 427-431.
9. Gurley BJ, Swain A,Williams DK, BaroneG, Battu SK. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John'swort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics.MolNutr Food Res. 2008; 52: 772-779.
10. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev. 1997; 27: 201-214.
11. Iwata H, Tezuka Y, Kadota S, Hiratsuka A,Watabe T. Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract. Drug Metab Dispos. 2004; 32: 1351-1358.
12. Iwasaki K, Matsuda H, Nagase K, Shiraga T, Tokuma Y, Uchida K. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. ResCommunChemPathol Pharmacol. 1993; 82: 209-216.
13. Jensen C, Jordan M, Shapiro R, Scantlebury V, Hakala T, Fung J, Starzl T, Venkataramanan R. Interaction between Tacrolimus and erythromycin. Lancet. 1994; 28: 280-281.
14. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K,VenkataramananR, StromS,ThummelK,Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001; 27: 383-391.
15. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest. 1998; 102: 1016-1023.
16. Liu JY,Wang YP, Liu HZ. Research progress of the chemical components and the pharmacology of schisandra chinensis. SpecialWild Economic Animal and Plant Research. 2005; 3: 49-53.
17. Mañez R, Martin M, Raman D, Silverman D, Jain A, Warty V, Gonzalez-Pinto I, Kusne S, Starzl TE. Fluconazole therapy in transplant recipients receiving FK506. Transplantation. 1994; 57: 1521-1523.
18. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004; 75: 13-33.
19. Merkle M,Wornle M, Rupprecht HD. The effect of sevelamer on tacrolimus target levels. Transplantation. 2005; 80: 707.
20. Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998; 18: 84-112.
21. MiuraM, Satoh S,Tada H, Saito M,KagayaH, Inoue K, Sagae Y, Kanno S, Ishikawa M, Habuchi T, Suzuki T. Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus. Int J Clin Pharmacol Ther. 2006; 44: 605-613.
22. Nagai H, Yakuo I, Aoki M, Teshima K, Ono Y, Sengoku T, Shimazawa T, Aburada M, Koda A. The Effect of Gomisin Aon Immunologic Liver Injury in Mice. Planta Meedica. 1989; 55: 13-17.
23. Ohno Y, Hisaka A, Ueno M, Suzuki H. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet. 2008; 47: 669-680.
24. Saitoh H, Saikachi Y, Kobayashi M, Yamaguchi M, Oda M, Yuhki Y, Achiwa K, Tadano K, Takahashi Y, Aungst BJ. Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine. European journal of pharmaceutical sciences. 2006; 28: 34-42.
25. Sun M, Xu X, Lu Q, Pan Q, Hu X, Schisandrin B. A dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1. Cancer Lett. 2007; 246: 300-307.
26. Saraeva RB, Paskaleva ID, Doncheva E, Eap CB, Ganev VS. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. J Clin Pharm Ther. 2007; 32: 641-649.
27. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992; 20: 753-761.
28. Vasquez EM, Pollak R, Benedetti E. Clotrimazole increases Tacrolimus blood levels: a drug interaction in kidney transplant recipients. Clin Transplant. 2001; 15: 95-99.
29. Venkataramanan R, Komoroski B, Strom S. In vitro and in vivo assessment of herb drug interactions. Life Sciences. 2006; 78: 2105-2115.
30. Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G, Scheller D, Ersfeld D, Frick M, Fitzsimmons WE, Virji M, Jain A, Brayman KL, Shaked A. Clinical utility of monitoring Tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol. 2001; 41: 542-551.
31. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S,Warty V, McMichael J, Lever J, Burckart G, Starzl T. Clinical pharmacokinetics of tacrolimus.Clin Pharmacokinet. 1995; 29: 404-430.
32. Zhang L, Niu X. Effects of Schizandrol A on Monomine Neurotransmitters in the Central Nervous System. Acta Academiae Medicinae Sinicae. 1991; 13: 13-16.